19 May 2021 – Mérieux Equity Partners, France (MxEP) has agreed to invest EUR 40 million into Swixx Biopharma AG, Switzerland (Swixx), taking a minority position. SIX listed HBM Healthcare Investments who had invested in Swixx in 2017, will co-invest alongside Mérieux, increasing HBM’s investment in Swixx by EUR 5 million. MxEP has arrangements in place to increase its investment in Swixx up to EUR 90 million, based upon the realisation of certain milestones.

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, and Russia. With 600 employees and sales exceeding EUR 260 million in 2021, Swixx is one of the largest and fastest-growing dedicated commercialization platform for biopharma and self-medication innovative companies in CEE. MxEP is an AMF-accredited management company dedicated to equity investments in the health and nutrition sector with currently over EUR 1 billion in assets under management.

Walder Wyss advised Swixx in this transaction. The team was led by Markus Vischer (Partner, Corporate/M&A, team leader) and Nico Bernhard (Senior Associate, Corporate/M&A) and further included Timon Nydegger and Michael Kissling (both Associates Corporate/M&A).